ZIKALIVAX 2.0 (Q3712907)
Jump to navigation
Jump to search
Project Q3712907 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | ZIKALIVAX 2.0 |
Project Q3712907 in France |
Statements
63,811.94 Euro
0 references
99,706.15 Euro
0 references
64.0 percent
0 references
1 September 2017
0 references
31 August 2019
0 references
UNIVERSITÉ DE LA RÉUNION
0 references
Les travaux menés par le post-doctorant visent à valider expérimentalement la souche virale atténuée ZIKALIVax comme un candidat vaccin vivant contre la fièvre ZIKA. (French)
0 references
The postdoctoral research aims at experimentally validating the attenuated viral strain ZIKALIVax as a live vaccine candidate against ZIKA fever. (English)
22 November 2021
0 references
Die Arbeit des Postdoktorats zielt darauf ab, den abgeschwächten Virusstamm ZIKALIVax experimentell als Kandidaten für Lebendimpfstoffe gegen ZIKA-Fieber zu validieren. (German)
2 December 2021
0 references
Het postdoctoraal onderzoek is gericht op het experimenteel valideren van de verzwakte virale stam ZIKALIVax als een levende vaccinkandidaat tegen ZIKA-koorts. (Dutch)
7 December 2021
0 references
La ricerca postdottorale mira a convalidare sperimentalmente il ceppo virale attenuato ZIKALIVax come vaccino vivo candidato contro la febbre ZIKA. (Italian)
13 January 2022
0 references
Identifiers
RE0012406
0 references